Eisai Co. vs Takeda Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eisai Co., Ltd. (4523.JP)

Q3 202630 Jun – 25 Sep 2026

▲4

Eisai Q3: Leqembi at-home approvals and oncology wins drive growth

Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.
This is a major new approval and launch that directly impacts Eisai's growth prospects.
Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.
Sales and royalty figures are key financial metrics showing Leqembi's market performance.
Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.
New approvals and validations in oncology represent additional growth drivers beyond Leqembi.
AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.
This strategic move may improve long-term R&D efficiency and is a new development.

August 202629 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

Latest29 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

July 202630 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

30 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

Takeda Pharmaceutical Co. Ltd. (4502.JP)

Q3 202613 Jul – 14 Sep 2026

▲4

Takeda's Q3: New Drug Launches and AI Partnerships Drive Growth

Qdenga approved in India Takeda's dengue vaccine Qdenga became India's first approved dengue vaccine, opening a large new market and boosting the company's global vaccine business.
This is a new approval that expands Takeda's vaccine reach and revenue potential.
ORZEYFUL launched in US and Japan ORZEYFUL, a first-in-class narcolepsy therapy, launched in the US and Japan, offering a new treatment option and adding a new revenue stream for Takeda.
This is a new product launch that directly contributes to Takeda's sales growth.
MIMRYLO approved for polycythemia vera MIMRYLO received FDA approval for polycythemia vera, expanding Takeda's oncology portfolio. However, it requires up to $1.15 billion in milestone payments to a partner.
This is a new approval that adds a new drug to Takeda's lineup, though with a financial obligation.
AI-developed zasocitinib beats Sotyktu in Phase 3 Zasocitinib, developed using AI, outperformed Sotyktu in a Phase 3 trial for psoriasis, and its NDA was accepted under priority review, with an FDA decision expected in early 2027.
This is a major clinical win that could lead to a new blockbuster drug, though approval is not yet certain.

August 202615 Aug – 14 Sep 2026

▲4

Takeda's pipeline wins and AI edge drive the story

AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.
It shows a technology edge that can drive future revenue and investor optimism.
Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.
A new approval expands Takeda's commercial portfolio and revenue potential.
FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.
A major U.S. approval adds a new growth driver, offset by milestone payments.
FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.
It advances a key pipeline drug toward market, a clear positive catalyst.

Latest15 Aug – 14 Sep 2026

▲4

Takeda's pipeline wins and AI edge drive the story

AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.
It shows a technology edge that can drive future revenue and investor optimism.
Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.
A new approval expands Takeda's commercial portfolio and revenue potential.
FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.
A major U.S. approval adds a new growth driver, offset by milestone payments.
FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.
It advances a key pipeline drug toward market, a clear positive catalyst.

July 202613 Jul – 11 Aug 2026

▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.
New approval expands market access and revenue potential for a key vaccine.
FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.
Major product approval with first-in-class status drives future earnings.
Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.
Strategic expansion into emerging market plasma supply adds growth optionality.
AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.
AI adoption may enhance R&D productivity and pipeline value.

13 Jul – 11 Aug 2026

▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.
New approval expands market access and revenue potential for a key vaccine.
FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.
Major product approval with first-in-class status drives future earnings.
Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.
Strategic expansion into emerging market plasma supply adds growth optionality.
AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.
AI adoption may enhance R&D productivity and pipeline value.

Q2 202618 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.

June 202618 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.

18 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.